{"id":4773,"date":"2025-12-16T15:58:16","date_gmt":"2025-12-16T07:58:16","guid":{"rendered":"https:\/\/credevo.com\/s\/?page_id=4773"},"modified":"2026-01-05T19:13:56","modified_gmt":"2026-01-05T11:13:56","slug":"emtricitabine-tenofovir-alafenamide-bioequivalence-study-protocol","status":"publish","type":"page","link":"https:\/\/credevo.com\/s\/emtricitabine-tenofovir-alafenamide-bioequivalence-study-protocol\/","title":{"rendered":"Emtricitabine\/Tenofovir Alafenamide Bioequivalence Study Protocol"},"content":{"rendered":"\n
\n

Emtricitabine\/Tenofovir Alafenamide (Descovy) is essential in HIV prevention and treatment, generating over $1.8 billion<\/strong> annually within a $30+ billion<\/strong> global market, with key patents expiring in 2025\u20132026 across major markets. Early generic entrants typically secure 70 – 80%<\/strong> of initial market volume during this transition period. Our streamlined bioequivalence protocol, optimized for this dual-NRTI combination’s predictable pharmacokinetics, supports a 6 – 8<\/strong> week development advantage for efficient market entry.<\/p>\n<\/blockquote>\n\n\n\n

<\/div>\n\n\n\n
\"Emtricitabine_Tenofovir_MoA_Credevo\"<\/figure>
\n

Overview<\/strong>: Emtricitabine\/Tenofovir Alafenamide (Descovy) is used for HIV-1 treatment and as pre-exposure prophylaxis (PrEP) to reduce the risk of infection and transmission, offering convenient once-daily dosing with minimal drug interactions. It is a fixed-dose nucleoside reverse transcriptase inhibitor (NRTI) combination that blocks HIV reverse transcriptase, with tenofovir alafenamide providing enhanced intracellular delivery and improved renal and bone safety compared to older formulations. A bioequivalence study confirms that generic formulations are equivalent to the reference product in terms of systemic exposure and pharmacokinetic profile, including TAF’s hepatic activation and emtricitabine’s linear kinetics.<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n

Download the complete, submission-ready BE protocol with all technical details<\/p>\n\n\n\n

What This Protocol Includes<\/p>\n\n\n\n

\n
\n
    \n
  • Study Synopsis<\/li>\n\n\n\n
  • Study Design Narrative<\/li>\n\n\n\n
  • PK Parameter Definitions (AUC, Cmax<\/sub>, Tmax<\/sub>, t\u00bd)<\/li>\n\n\n\n
  • Safety and AE\/ SAE Reporting<\/li>\n\n\n\n
  • Sampling Time Points<\/li>\n\n\n\n
  • Schedule of Assessments<\/li>\n<\/ul>\n<\/div>\n\n\n\n
    \n
      \n
    • Washout period<\/li>\n\n\n\n
    • Scientific Rationale & Regulatory Justification<\/li>\n\n\n\n
    • Dosing & Administration<\/li>\n\n\n\n
    • Inclusion\/ Exclusion Criteria<\/li>\n\n\n\n
    • Sample Handling <\/li>\n\n\n\n
    • Statistical Considerations<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n